|
|
|
|
Multiple Myeloma
Thalidomide Not Associated with Survival Improvement in Multiple ... 14 Mar 2006
Cancer Consultants (press release), ...reported that the addition of thalidomide to autologous stem cell transplantation does not improve survival for patients with newly diagnosed multiple myeloma. ...
APS: Callisto Announces Report Update from Equity Analyst ........ 14 Mar 2006
ANP Pers Support, ...development to treat relapsed multiple myeloma, a blood cancer. Atiprimod has entered. Phase I/IIa human clinical trials in relapsed multiple myeloma patients. ...
TODAY ON PHARMALIVE.COM 14 Mar 2006
PharmaLive.com (press release), ...terms described below. Callisto has also been developing Atiprimod as a therapy for multiple myeloma, a blood cancer. In light of ...
Children's Hospital gets influenza research grant 14 Mar 2006
Pharmaceutical Business Review Two projects involve cancer patients: those receiving stem cell transplants for multiple myeloma and patients with ovarian cancer receiving an experimental ...
How Can We Protect Patients With Weakened Immune Systems From ... 14 Mar 2006
PR Newswire (press release), Two projects involve cancer patients: those receiving stem cell transplants for multiple myeloma (a cancer originating in bone marrow) and patients with ...
Study: Thalidomide boosts short-term survival in multiple myeloma ... Mar 9, 2006
San Diego Union Tribune, In people over 65 – who are most likely to be diagnosed with the cancer multiple myeloma – thalidomide increased survival when added to milder chemotherapy ...
No Survival Advantage for Thalomid in Multiple Myeloma Mar 9, 2006
MedPage Today, LITTLE ROCK, Ark., March 9 - The addition of Thalomid (thalidomide) to high-dose chemotherapy for multiple myeloma led to improved complete responses and event ...
Thalidomide Improves Chemotherapy Efficacy in Elderly With ... Mar 10, 2006
Cancerpage.com, NEW YORK MAR 09, 2006 (Reuters Health) - In elderly patients with multiple myeloma, adding thalidomide to standard treatment with melphalan and prednisone ...
Study: Drug Aids Multiple Myeloma Patients Mar 9, 2006
The Westfall Weekly News, By LINDA A. JOHNSON, 1 minute ago. On the heels of disappointing results for thalidomide as a treatment for bone marrow cancer, a ...
Thalidomide Treatment for Multiple Myeloma Mar 9, 2006
Ivanhoe, ...(Ivanhoe Newswire) -- Doctors are calling the addition of thalidomide to the standard treatment for multiple myeloma a "historic moment in myeloma therapy.". ...
High-Dose Therapy Does Not Improve Multiple Myeloma Outcome Mar 9, 2006
Cancerpage.com, ...treatment with high-dose chemoradiotherapy offers no advantages in either progression-free or overall survival in patients with multiple myeloma, according to ...
Priority multiple myeloma review for Celgene drug Mar 7, 2006
Pharmaceutical Business Review Corporation a priority review designation for its supplemental new drug application for Revlimid for the treatment of relapsed or refractory multiple myeloma. ...
Thalidomide Beneficial in Multiple Myeloma Patients Ineligible for ... Mar 10, 2006
Cancer Consultants (press release), ...the addition of thalidomide to melphalan (Alkeran®) and prednisone appears beneficial in the treatment of elderly patients with multiple myeloma who are not ...
Updated Results with Velcade® in Multiple Myeloma Mar 3, 2006
Cancer Consultants (press release), ...published in the journal Cancer, updated results from a clinical trial evaluating Velcade® (bortezomib) in the treatment of multiple myeloma indicate long ...
Use of 99m Tc-Sestamibi Scintigraphy in Multiple Myeloma Mar 1, 2006
Journal of Nuclear Medicine Even-Sapir published in the August issue of The Journal of Nuclear Medicine (1). We would like to comment on the use of 99m Tc-sestamibi in multiple myeloma. ...
Thalidomide and Hematopoietic-Cell Transplantation for Multiple ... Mar 8, 2006
New England Journal of Medicine (subscription), Crowley, Ph.D. Background High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed ...
Experts Debate Thalidomide's Promise Against Myeloma Mar 10, 2006
Forbes March 10 (HealthDay News) -- The once-banned drug thalidomide appears to improve treatment for patients battling the blood cancer multiple myeloma, a new study ...
Velcade® plus Melphalan Shows Encouraging Activity in Multiple ... Feb 23, 2006
Cancer Consultants (press release), ...consisting of Velcade® (bortezomib) and melphalan (Alkeran®) provides encouraging anticancer activity in the treatment of multiple myeloma that has stopped ...
Thalidomide shows promise for ALS Mar 11, 2006
Monsters and Critics.com, Two other studies released this week indicated thalidomide could improve the treatment of elderly patients with a form of cancer known as multiple myeloma. ...
Drug fails in cancer study Mar 12, 2006
Indianapolis Star, ...ago but has been resurrected in recent years as a promising cancer treatment, failed in a study to prolong the lives of patients with multiple myeloma. ...
Thalidomide Gives Boost to Myeloma Therapy Mar 8, 2006
Forbes WEDNESDAY, March 8 (HealthDay News) -- Adding the formerly banned drug thalidomide to treatment for the blood cancer multiple myeloma boosted patient response ...
Study: Drug Aids Multiple Myeloma Patients Mar 9, 2006
ABC News In people over 65 who are most likely to be diagnosed with the cancer multiple myeloma thalidomide increased survival when added to milder chemotherapy, the ...
Thalidomide results mixed in UAMS study Mar 9, 2006
Arkansas Democrat Gazette, The drug thalidomide, made famous for causing birth defects, can prolong remission for some patients with multiple myeloma, but it was unable to increase ...
Thalidomide fights myeloma Mar 9, 2006
Health24.com, Adding the formerly banned drug thalidomide to treatment for the blood cancer multiple myeloma boosted patient response rates by nearly half, researchers report ...
New England Journal of Medicine Publishes Research by UAMS Team on ... Mar 9, 2006
PR Web (press release), A long-term study on the effectiveness of the drug thalidomide as part of the treatment for multiple myeloma, one of the least curable cancers, showed improved ...
New England Journal of Medicine Publishes Research By UAMS Team on ... Mar 9, 2006
PharmaLive.com (press release), ROCK, Ark., March 08, 2006 /PRNewswire/ -- A long-term study on the effectiveness of the drug thalidomide as part of the treatment for multiple myeloma, one of ...
Health & Fitness Mar 10, 2006
Burke Connection, Call 703-698-2841. Multiple Myeloma Group meets monthly to discuss experiences, emotions and challenges of living with multiple myeloma. ...
Millennium CEO says may form strategic partnership Mar 10, 2006
Reuters ...to cut costs, focus the company's research onto oncology and beef up the marketing of Velcade ahead of the introduction of a rival multiple myeloma drug from ...
McCarty Cancer Foundation Hosts Annual Gala To Raise Money and ... Mar 7, 2006
PR Newswire (press release), March 7 /PRNewswire/ -- The McCarty Cancer Foundation's eighth annual "Gathering for the Goal" gala will raise money for multiple myeloma cancer research on ...
Doubt cast on marrow cancer medication Mar 9, 2006
Boston Globe, ...a generation ago but been resurrected in recent years as a promising cancer treatment, did not prolong the lives of patients with multiple myeloma, a study has ...
New England Journal of Medicine Publishes Research By UAMS Team on ... Mar 8, 2006
Yahoo! News (press release) LITTLE ROCK, Ark., March 8 /PRNewswire/ -- A long-term study on the effectiveness of the drug thalidomide as part of the treatment for multiple myeloma, one of ...
Study Describes Osteonecrosis of the Jaw in Patients with Multiple ... Feb 27, 2006
Cancer Consultants (press release), A study published in the Journal of Clinical Oncology reports that risk of osteonecrosis of the jaw (ONJ) in patients with multiple myeloma may increase with ...
FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of ... Mar 3, 2006
International News Service, Review designation to its Supplemental New Drug Application (sNDA) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory multiple myeloma. ...
Diana Krall leads charity event for VGH & UBC Hospital Foundation ... Mar 7, 2006
CNW Telbec (Communiqués de presse), L/BMT) Program of British Columbia is world-renowned for its care for people from across BC with cancers of the blood such as leukemia and multiple myeloma. ...
Comparison of High-Dose to Standard-Dose Therapy in Multiple ... Feb 27, 2006
Cancer Consultants (press release), ...chemotherapy resulted in similar outcomes to treatment with high-dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma. ...
Thalomid With Chemotherapy Helps Older Myeloma Patients Mar 10, 2006
MedPage Today, Italy, March 10 - A second study in less than a week has found that Thalomid (thalidomide) has a place in first-line therapy for multiple myeloma patients, in ...
Thalidomide Uneffective In Myeloma Study Mar 9, 2006
Today's THV, A study carried out at the University of Arkansas for Medical Sciences concludes that thalidomide doesn't prolong the lives of patients with multiple myeloma. ...
Thalidomide improves remission in myeloma Mar 9, 2006
News-Medical.net, ...by a team from the University of Arkansas for Medical Sciences, examined the effectiveness of the drug Thalidomide as part of the treatment for multiple myeloma ...
Adding Thalidomide to Myeloma Therapy of Little Benefit Mar 9, 2006
Cancerpage.com, NEW YORK MAR 08, 2006 (Reuters Health) - Adding thalidomide to high-dose therapy for multiple myeloma makes complete responses more likely and increases event ...
Bolder Boulder was man's race Mar 13, 2006
Greeley Tribune, The Greeley resident, who died March 3 after a two-year battle with multiple myeloma, ran every one of them since it began 26 years ago. ...
BOTOX FOR PROSTATE ENLARGEMENT? Mar 11, 2006
Charlotte Sun-Herald, ...appropriately? She is about my age, 74. -- WA. ANSWER: Myeloma (also called multiple myeloma) is a cancer of the bone marrow. In ...
Thalidomide helps blood cancer cases Mar 9, 2006
The Age, ...market decades ago after causing severe birth defects in children but scientists in Italy said it could help patients suffering from multiple myeloma, a cancer ...
Jammed ER isn't EV hospital's only woe: Overcrowding, state ... Mar 12, 2006
TMCnet ...in Mesa. His seizures, doctors said, likely were brought on by dehydration and chemical imbalances from his multiple myeloma. The ...
Callisto Discusses Encouraging Anti-Tumor Responses of Drug ... Mar 7, 2006
Genetic Engineering News, This anti-cancer candidate has been in clinical development to treat patients with an advanced hematological cancer called Multiple Myeloma. ...
TopoTarget Announces Its Results for 2005 Mar 7, 2006
PharmaLive.com (press release), The most important of these milestones were: ® PXD101 - milestone payment from CuraGen after the initiation of Phase II multiple myeloma trials in Europe: On ...
XOMA Reports 2005 Results; Significant Revenue Growth and Other ... Mar 8, 2006
International News Service, ...patients with multiple myeloma. CHIR-12.12 is an anti-CD40. ... In October of 2005, we initiated a second Phase I study for patients with multiple myeloma ("MM"). ...
XOMA Reports 2005 Results; Significant Revenue Growth and Other ... Mar 8, 2006
Genetic Engineering News, ...agreement with Chiron. Then in October of 2005, we initiated a second Phase I study for patients with multiple myeloma. CHIR-12.12 ...
Myeloma group to host talk at Thursday luncheon Feb 20, 2006
Palm Beach Daily News, ..."What it Takes to Bring a New Multiple Myeloma Drug Through Development" will highlight a luncheon meeting from 11:30 am to 2 pm Thursday at the Palm Beach ...
Doxil® Associated with Fewer Heart Side Effects than Adriamycin® ... Feb 14, 2006
Cancer Consultants (press release), ...regimen referred to as VAD reduces the risk of serious side effects to the heart while maintaining effectiveness in the treatment of multiple myeloma. ...
Celgene's Revlimid Has Upside Long-Term Potential Mar 8, 2006
Forbes ...of key events lie on the horizon for Celgene (nasdaq: CELG - news - people ), including the pending approval of Revlimid for multiple myeloma, expected by the ...
Velcade Lung Cancer Study Begins Mar 6, 2006
TheStreet.com Take) and its partner Johnson & Johnson (JNJ:NYSE - commentary - research - Cramer's Take) have started trials to examine the multiple myeloma drug Velcade as ...
New Doubts On Thalidomide As Cancer Fighter Mar 9, 2006
All Headline News They looked at newly-diagnosed multiple myeloma patients who were given thalidomide on top of an already-grueling chemotherapy regimen. ...
Animal Data on Callisto's Drug Candidate Guanilib to Be Presented ... Mar 8, 2006
International News Service, Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer. Atiprimod has entered ...
Millennium Pharmaceuticals: more Velcade ventures Mar 7, 2006
Pharmaceutical Business Review It gained FDA approval in May 2003 for the third-line treatment of multiple myeloma patients who have shown disease progression since prior therapy. ...
Good Deeds | Everyday actions that inspire us Mar 11, 2006
Seattle Times, The doctors discovered that I had multiple myeloma, a cancer of the bone marrow that had caused eight compression fractures in my spine. ...
Doxil® in the VAD Regimen for Myeloma Confirmed Less Toxic Than ... Feb 28, 2006
Cancer Consultants (press release), ...and dexamethasone is associated with less toxicity than the conventional Adriamycin- (doxorubicin) based (VAD) induction regimen for multiple myeloma. ...
Celgene's Revlimid gets priority review Mar 3, 2006
United Press International SUMMIT, NJ, March 3 (UPI) -- Celgene said Friday the Food and Drug Administration granted Revlimid priority review for treatment of multiple myeloma. ...
North Port news briefs Mar 4, 2006
Charlotte Sun-Herald, For patients with blood cancers, such as non-Hodgkin's lymphoma and multiple myeloma, chemotherapy can be a double-edged sword. ...
Callisto Announces First Berlin Issues Research Update Following ... Mar 2, 2006
International News Service, ...and gastrointestinal tract. Callisto is also developing Atiprimod as a therapy for the blood cancer multiple myeloma. In the wake ...
SCIENCE NOTES Mar 10, 2006
Kentucky.com, In people over 65 -- who are most likely to have the cancer multiple myeloma -- thalidomide increased survival when added to milder chemotherapy, the newest ...
Millennium Achieves $10 Million Milestone Payment Mar 9, 2006
PharmaLive.com (press release), ..."This milestone payment reflects the continued worldwide growth of VELCADE, a market-leader in relapsed, refractory multiple myeloma, with more than 33,000 ...
TODAY ON PHARMALIVE.COM Mar 3, 2006
PharmaLive.com (press release), Atiprimod is presently in two Phase I/IIa clinical trials: 1) relapsed or refractory multiple myeloma patients, and 2) advanced cancer patients. ...
Celgene's Revlimid Gets Priority Review Mar 3, 2006
International News Service, Celgene said Friday the Food and Drug Administration granted Revlimid priority review for treatment of multiple myeloma. Celgene's ...
TODAY ON PHARMALIVE.COM Mar 2, 2006
PharmaLive.com (press release), ...statistics. Callisto is also developing Atiprimod as a potential drug therapy for multiple myeloma, a hematological cancer. The ...
Drug Rehab Feb 16, 2006
International News Service, Today thalidomide is widely used to treat multiple myeloma, a deadly blood-and-bone-marrow cancer that afflicts 50,000 people in the US Thalomid, Celgenes ...
Gate City cancer patient shocked by $3,780 copay for medication Feb 18, 2006
Kingsport Times News, Feb. 4 at a Weber City pharmacy, only her copay was $3,780. Pennington, 62, has multiple myeloma, a cancer of the plasma cell. It ...
Nereus’ $42.6M Sea Microbes Mar 6, 2006
Red Herring, As some of the proteins are linked to cancer, Nereus hopes the compound will treat people with multiple myeloma, lymphomas, and solid tumors.
NCCN Announces Important Updates to Kidney Cancer Clinical ... Mar 7, 2006
Genetic Engineering News, Patients, the Journal of the National Comprehensive Cancer Network (JNCCN), Cancer Resource Lines for Leukemia and Multiple Myeloma, educational conferences ...
Tobacco samples banned; legislator can breathe easy Mar 8, 2006
Yakima Herald-Republic, House. Oke has been open about his struggles with multiple myeloma, a rare cancer that targets plasma cells and weakens the bones. ...
(PRN) - EMCORE Announces New CX4 XFP for 10 Gigabit Applications . ... Mar 7, 2006
Bolsamania.com, 2006 ... [+. PRN) - McCarty Cancer Foundation Hosts Annual Gala To Raise Money and Awareness for Multiple Myeloma Research ... [+. ...
(PRN) - CapitolWatch Supports S. 2360: the Internet Non ... Mar 7, 2006
Bolsamania.com, ...(PRN) - McCarty Cancer Foundation Hosts Annual Gala To Raise Money and Awareness for Multiple Myeloma Research ... [+. PRN) - Atronic's ...
Hotline to focus on marrow problems Mar 9, 2006
Deseret News, Blood stem cell or bone marrow transplant may cure a variety of cancers, including leukemia, lymphoma, multiple myeloma and certain solid tumors such as ...
Thalidomide research at UAMS Mar 9, 2006
Arkansas Times, England Journal of Medicine reports today on results of research at UAMS on use of thalidomide to treat cancer patients with newly diagnosed multiple myeloma. ...
Millennium achieves $10M milestone payment Mar 9, 2006
Boston Mass High Tech, United States. Velcade is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.
This week in London Mar 6, 2006
London Free Press, Multiple Myeloma special presentation: Presentation by Kathleen Colson, Dana Farber Cancer Institute, on recent clinical trial results for Velcade, common side ...
Tumeric's healing powers studied Mar 7, 2006
Jackson Clarion Ledger, A second, more preliminary clinical trial is examining a safe and active dose of curcumin in patients with multiple myeloma, a rare cancer of the bone marrow. ...
AUDIO SUMMARY Mar 8, 2006
New England Journal of Medicine (subscription), ...and lamivudine for HBeAg-positive and HBeAg-negative chronic hepatitis B, thalidomide and hematopoietic-cell transplantation for multiple myeloma, birth and ...
Today's Caregiver Magazine Celebrates 50; Leading Caregiving ... Mar 7, 2006
Business Wire (press release), ...that the 50th interview is with Olympia means so much to my family since my father had suffered with bone pain as he battled multiple myeloma," Barg recounts. ...
Callisto's Cancer Drug Atiprimod to be Presented at Major ... Feb 15, 2006
Genetic Engineering News, ...the unique promise of Atiprimod, a potential anti-cancer treatment that is presently in a Phase I/IIa clinical trial in relapsed multiple myeloma patients. ...
Cytogen Reports Fourth Quarter and Full Year 2005 Financial ... Feb 23, 2006
MSN Money QUADRAMET is Cytogen's flagship product for the relief of pain due to metastatic bone disease arising from prostate, breast, multiple myeloma and other types ...
Keryx Biopharmaceuticals, Inc. Commences Phase 2, Multi-Center ... Mar 2, 2006
PharmaLive.com (press release), ...was announced earlier this year in connection with the initiation of a multi-center Phase II study evaluating perifosine as a treatment for multiple myeloma. ...
Antibodies are the first wave of IGF-1R antagonists for cancer ... Mar 6, 2006
TransWorldNews (press release), Pfizer is leading the field with the fully human IgG2 antibody CP-751,871 under investigation for multiple myeloma and advanced non-small cell lung cancer. ...
Infinity, Novartis In $400M Deal For Inhibitors Of Bcl-2 Mar 6, 2006
BioWorld Online (subscription), Its lead compound, an Hsp 90 inhibitor called IPI-504, is in two Phase I trials in multiple myeloma and in gastrointestinal stromal tumors. ...
Millennium and Johnson & Johnson Pharmaceutical Research & ... Mar 6, 2006
PR Newswire (press release), ...stage.(1). VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE ...
Kosan Reports 2005 Fourth Quarter and Year End Results Mar 2, 2006
Yahoo! News (press release) ...clinical activity of KOS-953 in combination with bortezomib (Velcade®) in patients with relapsed and relapsed refractory multiple myeloma; -- Advancement of ...
Going the extra mile Feb 11, 2006
Norman Transcript, When long-time Norman resident Lila Bowers was told she had multiple myeloma cancer, or cancer of the blood, she did what comes naturally: rise to the challenge ...
Nereus Raises $18.3M for Cancer Trials Mar 7, 2006
PharmaLive.com (press release), ...second compound, NPI-0052, is a highly potent proteasome inhibitor that will be tested for the treatment of patients with multiple myeloma, solid tumors and ...
Positive Findings From Clinical Studies of QUADRAMET(R) in ... Feb 27, 2006
International News Service, Skeletal invasion by prostate, breast, multiple myeloma, and other cancers often creates an imbalance between the normal process of bone destruction and ...
AEterna Zentaris Reports 2005 Fourth Quarter and Full-Year ... Mar 1, 2006
MSN Money ...without financial compensation payable; and - Perifosine: Initiation of Phase 2, multi-center study for the treatment of refractory multiple myeloma by partner ...
European Regulatory Committee Recommends Orphan Drug Status for ... Feb 14, 2006
Market Wire (press release) EMEA) has recommended the granting of orphan medicinal product designation for the anticancer monoclonal antibody 1D09C3 for the treatment of multiple myeloma. ...
Drug Stocks Tempered By Lofty Expectations Mar 4, 2006
Forbes The FDA granted Celgene the earlier designation on Revlimid for the treatment of multiple myeloma. The FDA action date is June 30. ...
166 Ho-DOTMP Radiation-Absorbed Dose Estimation for Skeletal ... Mar 1, 2006
Journal of Nuclear Medicine ...data from whole-body counting using a -camera or uptake probe were assessed for reproducibility of whole-body retention in 12 patients with multiple myeloma. ...
US Stock-Index Futures Fall on Rate Concern; JPMorgan Drops Mar 3, 2006
Bloomberg The drugmaker's Revlimid will receive priority review from the US Food and Drug Administration as a possible treatment for multiple myeloma, a cancer of the ...
(PZ) SmallCap Sentinel: Institutions Investing in Smaller Biotech ... Mar 1, 2006
Houston Chronicle, ...and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic ...
Millennium shares slip after downgrade Feb 28, 2006
BusinessWeek He said in a client note he sees a more robust competitive threat than previously projected for Velcade in the treatment of multiple myeloma, a cancer of the ...
Treatment, updates on multiple myeloma 25 Jan 2006
Jupiter Courier (subscription), Robert Jacobson, medical director of the Palm Beach Cancer Institute, and Registered Nurse Deborah Ford will provide updates on multiple myeloma treatment and ...
Once-Condemned Drug May Control Blood Cancer 25 Jan 2006
ABC News 270 patients, researchers looked at whether the controversial drug, thalidomide, would create a better treatment combination for multiple myeloma when taken ...
This jury used common sense 25 Jan 2006
Daily Mail - Charleston, The former Division of Highways worker suffers from multiple myeloma, a cancer of the plasma cells, an incurable but treatable disease. ...
Kosan Initiates Phase I Clinical Trial of Oral Hsp90 Inhibitor KOS ... 25 Jan 2006
Yahoo! News (press release) Herceptin®) in patients with Her2 positive breast cancer, as well as clinical trials in patients with relapsed refractory multiple myeloma (both as single ...
First Berlin Research, an Independent German Based Equity Research ... 25 Jan 2006
PharmaLive.com (press release), Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer. Atiprimod has entered ...
Velcade® Being Evaluated in Patients with Non-Hodgkin’s ... 25 Jan 2006
Cancer Consultants (press release), However, most of the research with this drug has focused on multiple myeloma. The US Food and Drug Administration (FDA) announced ...
Revlimid® Has Significant Activity in Chronic Lymphocytic ... 25 Jan 2006
Cancer Consultants (press release), ...to have fewer associated toxicities than thalidomide and has received fast-track designation from the FDA for the treatment of both MDS and multiple myeloma. ...
Millennium Announces Appointments of Executive Vice President of ... 25 Jan 2006
Yahoo! News (press release) ...experience. VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE ...
BiovaxID Yields 89% Survival in Patients with Aggressive Non ... 25 Jan 2006
DG News B-cell lymphocytes can undergo malignant transformation to become Non-Hogkin's lymphoma, multiple myeloma or chronic lymphocytic leukemia. ...
Thalomid Trial for Multiple Myeloma Achieves Primary Endpoint Jan 10, 2006
HealthCentral.com A clinical trial testing the drug Thalomid in patients with multiple myeloma was halted after the study achieved its primary endpoint, drug maker Celgene Corp. ...
Multiple Myeloma Research Foundation Awarded 4-Star Rating From ... Jan 11, 2006
Yahoo! News (press release) 11 /PRNewswire/ -- The Multiple Myeloma Research Foundation (MMRF) announced today that for a third consecutive year, the MMRF has received a 4-star rating ...
THALOMID(R) Pivotal Phase III Multiple Myeloma Trial Reaches Pre ... Jan 9, 2006
PR Newswire (press release), ...phase III study of combination thalidomide plus dexamethasone versus dexamethasone alone as induction therapy for previously untreated multiple myeloma met the ...
Celgene: Thalomid slows progression of multiple myeloma Jan 10, 2006
Pharmaceutical Business Review 10 Jan 2006, 17:56 GMT - Celegene has announced that it will halt a phase III trial of Thalomid plus dexamethasone in multiple myeloma after an analysis showed ...
Cytogen Announces Publication of Peer Reviewed Preclinical Data ... Jan 24, 2006
PR Newswire (press release), ...combination with the novel first-in-class proteasome inhibitor bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) for the treatment of multiple myeloma. ...
Velcade® Promising as Initial Therapy for Multiple Myeloma Jan 6, 2006
Cancer Consultants (press release), ...of Hematology (ASH), treatment with the agent Velcade® (bortezomib) produces high anti-cancer response rates in patients with newly-diagnosed multiple myeloma ...
Velcade® Has High Activity as Initial Therapy for Multiple ... Jan 3, 2006
Cancer Consultants (press release), ...the Salick Health Care Research Network have reported that Velcade (bortezomib) produces a 90% response rate in patients with newly diagnosed multiple myeloma. ...
Trigger for multiple myeloma relapse indentified Dec 28, 2005
Cancerfacts.com, ...a breakthrough discovery, researchers believe they have pinpointed the mechanism that triggers relapse in patients with a deadly cancer, called multiple myeloma ...
Initial Results Good in Lenalidomide/Dexamethasone Treatment of ... Dec 27, 2005
Cancerpage.com, NEW YORK DEC 26, 2005 (Reuters Health) - Treatment of newly diagnosed multiple myeloma with the thalidomide analog lenalidomide plus high-dose dexamethasone is ...
No Survival Benefit of High Dose Therapy in Multiple Myeloma Jan 5, 2006
Cancerpage.com, NEW YORK JAN 04, 2006(Reuters Health) - High-dose therapy (HDT) increases the complete remission rate in multiple myeloma patients responsive to chemotherapy ...
Oral Treatment Regimen Effective for Relapsed Multiple Myeloma Jan 3, 2006
Cancerpage.com, JAN 02, 2006 (Reuters Health) - Weekly cyclophosphamide and alternate-day prednisone are effective for patients with relapsed multiple myeloma after autologous ...
Thalidomide Improves Initial—not Overall—Response Rate in ... Dec 29, 2005
Cancer Consultants (press release), Thalidomide and the derivative Revlimid® (linalidomide) are considered important advances in the treatment of patients with multiple myeloma. ...
MDS Pharma Services Named Preferred Contract Research Organization ... Jan 23, 2006
Yahoo! News (press release) ...drug discovery and development solutions, has been selected as the preferred contract research organization (CRO) of the Multiple Myeloma Research Consortium ...
New Drug Could Stop The Spread Of Cancer Jan 24, 2006
13WHAM-TV, ...(Liz Bonis) 01/24/06 -- As part of a national trial, doctors are testing a new medication which could help people with multiple myeloma, a common cancer of the ...
Analysts' Stock Picks: Part 1 Jan 23, 2006
BusinessWeek 1950s and 1960s. The drug is now used to treat diseases including the blood cancer multiple myeloma, and leprosy. Werber says that ...
The Garden City Group, Inc. Makes a Donation in Memory of Co ... Jan 19, 2006
Business Wire (press release), ...(GCG) and its associates presented a contribution in the amount of $49,010.50 to The Multiple Myeloma Research Foundation (MMRF). ...
Pharmion Provides EU Registration Strategy Update for Thalidomide Jan 10, 2006
PR Newswire (press release), Newly-Released First Line Multiple Myeloma Data Expected to Form Basis of EU Submission BOULDER, Colo., Jan. 10 /PRNewswire-FirstCall ...
Addition of Thalomid® to Dexamethasone Improves Progression-Free ... Jan 9, 2006
Cancer Consultants (press release), ...that the addition of Thalomid® (thalidomide) to the steroid dexamethasone improves progression-free survival in patients with newly diagnosed multiple myeloma ...
(PRN) - Following Is a Test Release ... [+] Jan 24, 2006
Bolsamania.com,
| |
